No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Glassia is a market within the context of Endocrine and Metabolic Disorders Drugs. It is a biopharmaceutical product used to treat Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic disorder. Glassia is a liquid form of Alpha-1 Proteinase Inhibitor (A1PI) that is administered intravenously. It is designed to replace the missing or deficient A1PI in the body, which helps to reduce the risk of lung and liver damage associated with AATD. Glassia is the only FDA-approved A1PI replacement therapy for AATD.
The Glassia market is composed of a number of companies, including Grifols, CSL Behring, and Kamada. Grifols is a global healthcare company that produces and distributes Glassia, as well as other biopharmaceutical products. CSL Behring is a biopharmaceutical company that specializes in the development and production of plasma-derived therapies, including Glassia. Kamada is an Israeli biopharmaceutical company that produces and distributes Glassia, as well as other biopharmaceutical products. Show Less Read more
